I want to adjust ceftraixone sulbatum plus disodium edetate according to GFR how dose is adjusted
Reading File
Finding Sources
Searching the Web
ceftriaxone sulbactam disodium edetate dose adjustment GFR renal impairment
Searching PubMed
ceftriaxone sulbactam renal dose adjustment
Searching the Web
ceftriaxone sulbactam edetate disodium combination India prescribing information renal dose CrCl
Finding Sources
Reading Web Page
renal dose adjustment GFR creatinine clearance sulbactam ceftriaxone
Searching the Web
sulbactam dose adjustment GFR CrCl less than 30 renal failure beta-lactamase inhibitor
Here is a comprehensive, evidence-based guide to dose adjustment of Ceftriaxone + Sulbactam + Disodium Edetate (EDTA) according to GFR/CrCl.
Understanding the Combination
This is a triple-component injectable antibiotic used in India and some other Asian/African countries (marketed as Sulbactomax, Magnamycin SB, etc.):
- Ceftriaxone - 3rd generation cephalosporin (biliary + renal excretion, ~50/50)
- Sulbactam - beta-lactamase inhibitor (predominantly renal excretion, ~75-85% unchanged in urine)
- Disodium edetate (EDTA) - chelating agent added to enhance outer membrane permeability of gram-negative bacteria; no significant pharmacokinetic adjustment needed for renal impairment
Because ceftriaxone and sulbactam have different excretion pathways, they require separate dose-adjustment considerations.
Dose Adjustment by GFR/CrCl
Ceftriaxone Component
| GFR / CrCl | Adjustment |
|---|---|
| >10 mL/min | No dose adjustment needed |
| <10 mL/min (preterminal renal failure) | Cap dose at maximum 2 g/day |
| Hemodialysis | No supplemental dose required (not removed by HD or peritoneal dialysis) |
| Combined hepatic + significant renal impairment | Cap at 2 g/day with close monitoring |
- Rationale: Ceftriaxone is excreted via both bile and kidneys. In renal failure, biliary excretion compensates, but there is still some accumulation - monitoring is advised. Package insert confirms this approach.
Sulbactam Component
Sulbactam is ~75-85% renally cleared and requires dose/interval adjustment based on CrCl. Since this combination is typically given as ceftriaxone:sulbactam in a 2:1 ratio (e.g., 1 g:500 mg or 2 g:1 g), the sulbactam interval drives the dosing schedule in renal impairment:
| CrCl (mL/min) | Sulbactam Interval Adjustment | Practical Combined Dose |
|---|---|---|
| >30 mL/min | No adjustment needed | Usual dose q12h or q24h |
| 15-29 mL/min | Extend interval to q12h | Reduce to q12h |
| <15 mL/min (including ESRD) | Extend interval to q24h | Reduce to q24h |
| Hemodialysis | Dose as CrCl <15; give after dialysis on HD days | Once daily, post-HD |
| CAPD | Dose as CrCl <15 | q24h |
(Based on ampicillin-sulbactam renal adjustment data, which is the reference standard for sulbactam pharmacokinetics.)
Combined Practical Dosing Table
| GFR/CrCl | Ceftriaxone + Sulbactam Regimen |
|---|---|
| >50 mL/min | Normal dose (e.g., 1.5 g or 3 g) q12-24h as clinically indicated |
| 30-50 mL/min | No change required; monitor |
| 15-29 mL/min | Reduce frequency to q12h; cap ceftriaxone at 2 g/day if also hepatically impaired |
| <15 mL/min / ESRD | Reduce frequency to q24h; cap ceftriaxone at 2 g/day |
| Hemodialysis | q24h; administer after dialysis on dialysis days |
| Hepatic + renal impairment | Max ceftriaxone equivalent 2 g/day regardless of CrCl |
Key Clinical Points
-
Disodium EDTA has no renal-clearance issue and does not alter the dosing schedule.
-
Sulbactam accumulates in renal failure - the dose adjustment is primarily an interval extension, not a dose reduction. This mirrors the ampicillin-sulbactam protocol.
-
GFR <10 mL/min: Both components need attention - ceftriaxone capped at 2 g/day AND sulbactam given q24h.
-
Hemodialysis: Ceftriaxone is NOT dialyzed; sulbactam IS partially dialyzed - give dose after HD.
-
Combined hepatic + renal failure: The most restrictive scenario - max 2 g/day ceftriaxone equivalent with serum level monitoring where available.
-
Elderly patients: No modification needed if renal and hepatic function is satisfactory (but check actual CrCl - don't rely on serum creatinine alone in the elderly).
Note: Specific Indian formulations (e.g., Sulbactomax 1.5 g = ceftriaxone 1 g + sulbactam 500 mg + EDTA 10 mg) may have slightly different prescribing inserts. Always cross-check the manufacturer's package insert for your specific brand, as the EDTA component and exact ratios can differ. This guidance is derived from the pharmacokinetics of the individual components.
And how amikacin dose is adjusted according to gfr
Finding Sources
Searching the Web
amikacin dose adjustment GFR CrCl renal impairment dosing table 2024
Finding Sources
Reading Web Page
amikacin dose adjustment CrCl GFR renal impairment hemodialysis
Finding Sources
Searching the Web
amikacin traditional dosing Hartford nomogram interval extension renal impairment trough peak targets
Here is a complete, evidence-based guide to amikacin dose adjustment by GFR/CrCl.
Key Principles Before Dosing
- Amikacin is ~95-99% renally excreted - it accumulates dangerously in renal impairment
- Always use CrCl (Cockcroft-Gault), NOT eGFR for amikacin dosing - this is critical and widely agreed upon
- Use Ideal Body Weight (IBW) for non-obese patients; Adjusted Body Weight (AdjBW) for obese (BMI >30)
- Concentration-dependent killing - efficacy depends on peak:MIC ratio; toxicity depends on trough/exposure duration
- Two dosing strategies exist: Extended Interval (once-daily) and Conventional (multiple daily doses)
Cockcroft-Gault Formula (to calculate CrCl)
CrCl (mL/min) = [(140 - age) x IBW] / (72 x SCr) x 0.85 (for females)
- If SCr <1 mg/dL and age >65, round Scr up to 1.0
- Use actual body weight if less than IBW
Strategy 1: Extended Interval Dosing (Once-Daily) - Preferred
Used for most gram-negative infections. Uses the Hartford Nomogram for interval adjustment.
Standard Starting Dose: 15 mg/kg (AdjBW) IV
| CrCl (mL/min) | Initial Dosing Interval |
|---|---|
| >60 | q24h |
| 40-59 | q36h |
| 20-39 | q48h |
| <20 | Not recommended - switch to conventional dosing with level monitoring |
| Hemodialysis | Not recommended - use conventional dosing |
For nosocomial/severe infections (HAP/VAP, sepsis): 20 mg/kg q24h starting dose
Exclusions from extended-interval dosing:
- CrCl <30 mL/min (most protocols) or <20 mL/min (stricter protocols)
- Rapidly changing renal function
- Pregnancy
- Gram-positive synergy dosing (endocarditis)
- Burns >20%, ascites, large third-space fluid shifts
Strategy 2: Conventional (Traditional/Multiple Daily) Dosing
Used when extended-interval is excluded (renal impairment, special populations).
Standard Dose: 7.5 mg/kg q12h (15 mg/kg/day)
| CrCl (mL/min) | Dose Adjustment |
|---|---|
| >70 | No adjustment; 7.5 mg/kg q12h or 15 mg/kg q24h |
| 50-70 | 7.5 mg/kg q12h (no change, monitor levels) |
| 30-50 | Reduce dose by ~50-67% (5 mg/kg q12h) OR extend interval |
| 10-30 | Reduce dose by 67-75% (5 mg/kg q24h OR 10 mg/kg q48h) |
| <10 / ESRD | 7.5 mg/kg q48-72h; dose guided strictly by levels |
| Hemodialysis | 5-7.5 mg/kg per session; give after HD; redose based on post-HD trough |
| CAPD | 5 mg/kg q48h; level-guided |
A practical simplified table (UK hospital protocol):
| CrCl (mL/min) | Once-Daily Dose | Interval |
|---|---|---|
| >80 | 15 mg/kg (max 1.5 g) | q24h |
| 60-79 | 12 mg/kg (max 1.5 g) | q24h |
| 40-59 | 7.5 mg/kg (max 1.5 g) | q24h |
| 30-39 | 4 mg/kg (max 1.5 g) | q24h |
| <30 | Avoid if possible. If essential: 3-4 mg/kg (max 320 mg), single dose only; check level at 24h and discuss with ID/Microbiology before re-dosing | |
| HD | 5 mg/kg (max 400 mg) per session, post-dialysis |
Therapeutic Drug Monitoring (TDM) - Mandatory
Extended-Interval (Hartford Nomogram Method)
- Draw a random level 6-14 hours after start of first infusion
- For amikacin: divide the measured level by 2, then plot on the Hartford nomogram
- The nomogram determines the interval (q24h / q36h / q48h)
- Target trough: <4 mg/L (ideally undetectable)
- Target peak: 40-60 mg/L (for serious infections)
Conventional Dosing
| Parameter | Target |
|---|---|
| Peak (30 min post-infusion) | 20-30 mg/L (general); 25-40 mg/L (life-threatening) |
| Trough (30 min pre-dose) | <5 mg/L (ideally <2-4 mg/L to avoid nephrotoxicity) |
- Draw trough just before 3rd or 4th dose (steady state)
- In renal impairment / elderly: draw level before the 2nd dose and hold until result available
Pediatric GFR-Based Adjustment (Traditional Dosing: 5 mg/kg q8h)
| GFR (mL/min/1.73m²) | Interval |
|---|---|
| 30-50 | q12-18h |
| 10-29 | q18-24h |
| <10 | q48-72h |
| HD/PD | 5 mg/kg/dose; redose guided by serum concentrations |
Key Monitoring Parameters
| Parameter | Frequency |
|---|---|
| Serum creatinine / CrCl | Before each dose in renal impairment |
| Drug levels (peak + trough) | Before 3rd dose (conventional); 6-14h post 1st dose (EID) |
| Urine output | Daily |
| Audiometry | If >2 weeks of therapy |
| Vestibular assessment | If prolonged use or complaints of dizziness |
Clinical Pearls
- Nephrotoxicity is related to prolonged trough exposure - keep trough <5 mg/L
- Ototoxicity (cochlear and vestibular) is related to cumulative dose and duration - irreversible
- In rapidly changing renal function (AKI), CrCl can change hour to hour - daily level monitoring is essential and EID should be avoided
- Augmented renal clearance (CrCl >130 mL/min, common in young ICU patients) - may need higher or more frequent doses; don't underdose
- Maximum cumulative course dose: ~15 g total per course in most protocols; consult ID/Microbiology if exceeding
This is a shared conversation. Sign in to Orris to start your own chat.